1072833-77-2 Usage
Description
(R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutylboronic acid, also known as the active metabolite of ixazomib citrate, is a glycine derivative with potent anticancer properties. It is derived from the formal condensation of the carboxy group of N-(2,5-dichlorobenzoyl)glycine with the amino group of [(1R)-1-amino-3-methylbutyl]boronic acid. (R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutylboronic acid plays a crucial role in the treatment of multiple myeloma and exhibits potential neurotoxicity.
Uses
Used in Oncology:
(R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutylboronic acid is used as an anticancer agent for the treatment of patients with multiple myeloma. It functions as a proteasome inhibitor, preventing cell growth in solid tumors and thus targeting cancer cells effectively.
Used in Combination Therapy:
In the field of oncology, (R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutylboronic acid is utilized in combination therapy to enhance the treatment outcomes for multiple myeloma patients. The synergistic effects of this compound with other anticancer agents contribute to improved efficacy and potentially better patient outcomes.
Check Digit Verification of cas no
The CAS Registry Mumber 1072833-77-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,7,2,8,3 and 3 respectively; the second part has 2 digits, 7 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1072833-77:
(9*1)+(8*0)+(7*7)+(6*2)+(5*8)+(4*3)+(3*3)+(2*7)+(1*7)=152
152 % 10 = 2
So 1072833-77-2 is a valid CAS Registry Number.
1072833-77-2Relevant articles and documents
A solid-phase approach for the synthesis of α-Aminoboronic acid peptides
Daniels, Blake E.,Stivala, Craig E.
, p. 3343 - 3347 (2018)
A solid-phase synthesis of α-Aminoboronic acid peptides using a 1-glycerol polystyrene resin is described. Standard Fmoc solid-phase peptide chemistry is carried out to construct bortezomib and ixazomib. This approach eliminates the need for liquid-liquid extractions, silica gel column chromatography, and HPLC purifications, as products are isolated in high purity after direct cleavage from the resin.
Synthetic process research of ixazomib
-
Paragraph 0004; 0012, (2019/11/04)
The invention discloses a synthesis method of ixazomib. The yield and the purity of a target product can be greatly increased with the method.
Novel boric acid salicylate derivatives and pharmaceutical composition thereof
-
Paragraph 0096; 0118-0122, (2019/08/06)
The invention discloses novel boric acid salicylate derivatives and pharmaceutical composition thereof and also provides pharmaceutically acceptable salt, a preparation method, an application of the pharmaceutical composition of the derivatives. The provided compounds have a remarkable inhibition function on tumor cells, can be used for preventing and/or treating tumor-related diseases, especiallymultiple myeloma and have broad application prospects.